Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples

Woo, Chang Gok; Son, Seung-Myoung; Lee, Ho-Chang; Han, Hye Sook; Lee, Ki Hyeong; Kim, Dohun; Kim, Eung‐Gook; Lee, Ok-Jun

doi:10.4143/crt.2021.773

Cited by 8 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main mechanism described is resistance to inhibition of the EGFR pathway. A recent case series described several histologic transitions from ADC to SCC [ 55 ]. Moreover, in EGFR mutated cohort resistant to chemotherapy, it was reported a transition to SCC in 14% of 37 NSCLC cases [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases

Bonis

Dell’Amore

Verzeletti

et al. 2023

JCM

View full text Add to dashboard Cite

In a Surgical Thoracic Center, two females and a man were unexpectedly diagnosed with hepatoid adenocarcinoma of the lung (HAL) in a single year. HAL is a rare lung cancer with pathological features of hepatocellular carcinoma with no evidence of liver tumor or other primitive sites of neoplasms. As of today, a comprehensive treatment is still not written. We reviewed the most updated literature on HAL, aiming to highlight the proposed treatments available, and comparing them in terms of survival. General hallmarks of HAL are confirmed: it typically affects middle-aged, heavy-smoker males with a median of 5 cm bulky right upper lobe mass. Overall survival remains poor (13 months), with a longer but non-significant survival in females. Treatments are still unsatisfactory today: surgery guarantees a small benefit compared to non-operated HALs, and only N0 patients demonstrated improved survival (p = 0.04) compared to N1, N2, and N3. Even though the histology is fearsome, these are probably the patients who will benefit from upfront surgery. Chemotherapy seemed to behave as surgery, and there is no statistical difference between chemotherapy only, surgery, or adjuvant treatments, even though adjuvant treatments tend to be more successful. New chemotherapies have been reported with notable results in recent years, such as Tyrosine Kinase Inhibitors and monoclonal antibodies. In this complicated picture, new cases are needed to further build shared evidence in terms of diagnosis, treatments, and survival opportunities.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases

Bonis

Dell’Amore

Verzeletti

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In the same lines, the immune infiltrate in tumors can also be heterogeneously distributed, and some tumors present immune infiltration only in the periphery while the central tumor area is immunologically “cold”, constituting the immune excluded tumor type; thus, strategies should take these features into consideration ( 28 , 29 ). Another example of heterogeneity that must be taken into account is the temporal heterogeneity of the different expression of biomarkers like PD-L1 in different stages of tumor progression, or the changes of histological type and mutation status during lung cancer targeted therapy ( 30 , 31 ). Thus, monitoring the changes on biomarker profile within the context of histological features is extremely important for immune-oncology research.…”

Section: Profiling Of Different Types Of Tumors Using Dspmentioning

confidence: 99%

Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler

et al. 2022

View full text Add to dashboard Cite

Characterization of the tumor microenvironment through immunoprofiling has become an essential resource for the understanding of the complex immune cell interactions and the assessment of biomarkers for prognosis and prediction of immunotherapy response; however, these studies are often limited by tissue heterogeneity and sample size. The nanoString GeoMx® Digital Spatial Profiler (DSP) is a platform that allows high-plex profiling at the protein and RNA level, providing spatial and temporal assessment of tumors in frozen or formalin-fixed paraffin-embedded limited tissue sample. Recently, high-impact studies have shown the feasibility of using this technology to identify biomarkers in different settings, including predictive biomarkers for immunotherapy in different tumor types. These studies showed that compared to other multiplex and high-plex platforms, the DSP can interrogate a higher number of biomarkers with higher throughput; however, it does not provide single-cell resolution, including co-expression of biomarker or spatial information at the single-cell level. In this review, we will describe the technical overview of the platform, present current evidence of the advantages and limitations of the applications of this technology, and provide important considerations for the experimental design for translational immune-oncology research using this tissue-based high-plex profiling approach.

show abstract

“…However, they have also been reported in patients with NSCLC undergoing treatment without EGFR-TKIs and in those with other cancers. [30][31][32][33] For example, HTs to SCLC after programmed cell death 1 (PD-1) inhibitor treatment has also been reported. In addition, HTs of adenocarcinoma to SqCC and vice versa have been reported after treatment with PD-1 inhibitors such as nivolumab, pembrolizumab, and sintilimab.…”

Section: Ht Induced By Agents Other Than Egfr-tkismentioning

confidence: 99%

Histologic transformation in lung cancer: when one door shuts, another opens

2022

View full text Add to dashboard Cite

Histologic transformation (HT) is a major cause of drug resistance to therapy in patients with lung cancer. HTs to small-cell lung cancer (SCLC) have been reported frequently in patients with epidermal growth factor receptor ( EGFR)-mutated lung cancer. Although HTs have an impact on the clinical outcomes in patients owing to a high refractoriness to treatments, there is limited data on the prevalence, causes, mechanisms, treatment efficacy, and future treatment strategies. In this review, we assess the literature regarding HTs comprehensively, including those describing EGFR-tyrosine kinase inhibitors, other molecular targeted drugs, and immune checkpoint inhibitors. Furthermore, we discuss the mechanisms of HTs and the lineage plasticity to SCLC and squamous cell carcinoma in lung cancer. In addition, we summarize the treatment efficacy and future perspectives of HTs in patients with lung cancer, and propose better management strategies for this group of patients.

show abstract

Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples

Cited by 8 publications

References 18 publications

Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases

Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases

Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler

Histologic transformation in lung cancer: when one door shuts, another opens

Contact Info

Product

Resources

About